BM-MSCs derived from AML patients, have been shown to release higher levels of the proinflammatory chemokine C-X-C motif ligand 8 (CXCL8) compared to BM-MSCs isolated from healthy counterparts (Cheng et al., 2019). This evidence concerns the gene CXCL8 and acute myeloid leukemia.